In adrenocortical cancer, GPER1 presented tumor suppressive properties as GPER1 agonists suppressed adrenocortical carcinoma proliferation via cell cycle arrest, DNA damage, and apoptosis via ERK1/2 activation [18]. This evidence concerns the gene MAPK3 and adrenal cortex carcinoma.